Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free IDHC Stock Alerts

Integrated Diagnostics (IDHC) Competitors

Integrated Diagnostics logo
GBX 0.61 +0.04 (+7.42%)
As of 12:03 PM Eastern
Compare

IDHC vs. VRCI, AGL, PRM, GENI, and DMTR

Should you buy Integrated Diagnostics stock or one of its competitors? MarketBeat compares Integrated Diagnostics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Integrated Diagnostics include Verici Dx (VRCI), ANGLE (AGL), Proteome Sciences (PRM), GENinCode (GENI), and Deepmatter Group (DMTR).

How does Integrated Diagnostics compare to Verici Dx?

Integrated Diagnostics (LON:IDHC) and Verici Dx (LON:VRCI) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

In the previous week, Integrated Diagnostics had 1 more articles in the media than Verici Dx. MarketBeat recorded 1 mentions for Integrated Diagnostics and 0 mentions for Verici Dx. Integrated Diagnostics' average media sentiment score of 1.11 beat Verici Dx's score of 0.00 indicating that Integrated Diagnostics is being referred to more favorably in the media.

Company Overall Sentiment
Integrated Diagnostics Positive
Verici Dx Neutral

Integrated Diagnostics has a net margin of 17.20% compared to Verici Dx's net margin of -193.05%. Integrated Diagnostics' return on equity of 38.79% beat Verici Dx's return on equity.

Company Net Margins Return on Equity Return on Assets
Integrated Diagnostics17.20% 38.79% 9.69%
Verici Dx -193.05%-138.93%-26.14%

Integrated Diagnostics has higher revenue and earnings than Verici Dx. Verici Dx is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Integrated Diagnostics£8.35B0.00£4.01T£250.030.00
Verici Dx£3.66M2.04-£6.56M-£0.90N/A

Integrated Diagnostics has a beta of 0.376, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Verici Dx has a beta of 1.256, meaning that its stock price is 26% more volatile than the broader market.

7.7% of Integrated Diagnostics shares are held by institutional investors. Comparatively, 7.9% of Verici Dx shares are held by institutional investors. 71.3% of Integrated Diagnostics shares are held by insiders. Comparatively, 1.3% of Verici Dx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Integrated Diagnostics beats Verici Dx on 10 of the 13 factors compared between the two stocks.

How does Integrated Diagnostics compare to ANGLE?

Integrated Diagnostics (LON:IDHC) and ANGLE (LON:AGL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

Integrated Diagnostics has higher revenue and earnings than ANGLE. ANGLE is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Integrated Diagnostics£8.35B0.00£4.01T£250.030.00
ANGLE£2.62M2.89-£21.76M-£4.80N/A

In the previous week, Integrated Diagnostics had 1 more articles in the media than ANGLE. MarketBeat recorded 1 mentions for Integrated Diagnostics and 0 mentions for ANGLE. Integrated Diagnostics' average media sentiment score of 1.11 beat ANGLE's score of 0.76 indicating that Integrated Diagnostics is being referred to more favorably in the media.

Company Overall Sentiment
Integrated Diagnostics Positive
ANGLE Positive

Integrated Diagnostics has a beta of 0.376, meaning that its stock price is 62% less volatile than the broader market. Comparatively, ANGLE has a beta of 0.22, meaning that its stock price is 78% less volatile than the broader market.

Integrated Diagnostics has a net margin of 17.20% compared to ANGLE's net margin of -1,444.04%. Integrated Diagnostics' return on equity of 38.79% beat ANGLE's return on equity.

Company Net Margins Return on Equity Return on Assets
Integrated Diagnostics17.20% 38.79% 9.69%
ANGLE -1,444.04%-191.36%-29.89%

7.7% of Integrated Diagnostics shares are held by institutional investors. Comparatively, 17.5% of ANGLE shares are held by institutional investors. 71.3% of Integrated Diagnostics shares are held by insiders. Comparatively, 2.7% of ANGLE shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Integrated Diagnostics beats ANGLE on 11 of the 13 factors compared between the two stocks.

How does Integrated Diagnostics compare to Proteome Sciences?

Proteome Sciences (LON:PRM) and Integrated Diagnostics (LON:IDHC) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

0.0% of Proteome Sciences shares are held by institutional investors. Comparatively, 7.7% of Integrated Diagnostics shares are held by institutional investors. 36.7% of Proteome Sciences shares are held by company insiders. Comparatively, 71.3% of Integrated Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Integrated Diagnostics had 1 more articles in the media than Proteome Sciences. MarketBeat recorded 1 mentions for Integrated Diagnostics and 0 mentions for Proteome Sciences. Integrated Diagnostics' average media sentiment score of 1.11 beat Proteome Sciences' score of 0.00 indicating that Integrated Diagnostics is being referred to more favorably in the news media.

Company Overall Sentiment
Proteome Sciences Neutral
Integrated Diagnostics Positive

Integrated Diagnostics has higher revenue and earnings than Proteome Sciences. Proteome Sciences is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Proteome Sciences£3.76M1.49-£4.08M-£1.04N/A
Integrated Diagnostics£8.35B0.00£4.01T£250.030.00

Proteome Sciences has a beta of 0.148, meaning that its stock price is 85% less volatile than the broader market. Comparatively, Integrated Diagnostics has a beta of 0.376, meaning that its stock price is 62% less volatile than the broader market.

Integrated Diagnostics has a net margin of 17.20% compared to Proteome Sciences' net margin of -81.50%. Integrated Diagnostics' return on equity of 38.79% beat Proteome Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Proteome Sciences-81.50% 33.80% -19.25%
Integrated Diagnostics 17.20%38.79%9.69%

Summary

Integrated Diagnostics beats Proteome Sciences on 12 of the 13 factors compared between the two stocks.

How does Integrated Diagnostics compare to GENinCode?

GENinCode (LON:GENI) and Integrated Diagnostics (LON:IDHC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

In the previous week, GENinCode and GENinCode both had 1 articles in the media. Integrated Diagnostics' average media sentiment score of 1.11 beat GENinCode's score of 0.00 indicating that Integrated Diagnostics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GENinCode
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Integrated Diagnostics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

GENinCode has a beta of 0.593, meaning that its share price is 41% less volatile than the broader market. Comparatively, Integrated Diagnostics has a beta of 0.376, meaning that its share price is 62% less volatile than the broader market.

11.4% of GENinCode shares are owned by institutional investors. Comparatively, 7.7% of Integrated Diagnostics shares are owned by institutional investors. 8.4% of GENinCode shares are owned by company insiders. Comparatively, 71.3% of Integrated Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Integrated Diagnostics has higher revenue and earnings than GENinCode. GENinCode is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GENinCode£3.08M2.04-£6.10M-£2.08N/A
Integrated Diagnostics£8.35B0.00£4.01T£250.030.00

Integrated Diagnostics has a net margin of 17.20% compared to GENinCode's net margin of -185.47%. Integrated Diagnostics' return on equity of 38.79% beat GENinCode's return on equity.

Company Net Margins Return on Equity Return on Assets
GENinCode-185.47% -409.40% -63.99%
Integrated Diagnostics 17.20%38.79%9.69%

Summary

Integrated Diagnostics beats GENinCode on 9 of the 12 factors compared between the two stocks.

How does Integrated Diagnostics compare to Deepmatter Group?

Integrated Diagnostics (LON:IDHC) and Deepmatter Group (LON:DMTR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

Integrated Diagnostics has a net margin of 17.20% compared to Deepmatter Group's net margin of 0.00%. Integrated Diagnostics' return on equity of 38.79% beat Deepmatter Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Integrated Diagnostics17.20% 38.79% 9.69%
Deepmatter Group N/A N/A N/A

7.7% of Integrated Diagnostics shares are held by institutional investors. 71.3% of Integrated Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Integrated Diagnostics has higher revenue and earnings than Deepmatter Group. Deepmatter Group is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Integrated Diagnostics£8.35B0.00£4.01T£250.030.00
Deepmatter Group£1.04M0.00N/A-£0.30N/A

In the previous week, Integrated Diagnostics had 1 more articles in the media than Deepmatter Group. MarketBeat recorded 1 mentions for Integrated Diagnostics and 0 mentions for Deepmatter Group. Integrated Diagnostics' average media sentiment score of 1.11 beat Deepmatter Group's score of 0.00 indicating that Integrated Diagnostics is being referred to more favorably in the media.

Company Overall Sentiment
Integrated Diagnostics Positive
Deepmatter Group Neutral

Summary

Integrated Diagnostics beats Deepmatter Group on 10 of the 10 factors compared between the two stocks.

Get Integrated Diagnostics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IDHC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IDHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IDHC vs. The Competition

Export
MetricIntegrated DiagnosticsLife Sciences Tools & Services IndustryHealthcare SectorLON Exchange
Market Cap£3.53M£9.22B£6.93B£2.87B
Dividend Yield1.42%1.47%2.60%6.13%
P/E Ratio0.0062.26281.16369.49
Price / Sales0.00260.94576.6583,955.53
Price / CashN/A25.9671.7927.89
Price / Book0.0038.1112.867.07
Net Income£4.01T£57.47B£3.49B£5.89B
7 Day Performance4.11%1.35%2.65%1.18%
1 Month Performance19.22%-2.30%-2.63%0.90%
1 Year Performance60.85%19.18%76.00%75.31%

Integrated Diagnostics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IDHC
Integrated Diagnostics
N/AGBX 0.61
+7.4%		N/A+56.4%£3.53M£8.35B0.006,692
VRCI
Verici Dx
N/AGBX 0.37
+5.7%		N/A-56.4%£11.05M£3.66MN/A19
AGL
ANGLE
N/AGBX 2.35
-11.3%		N/A-59.8%£7.58M£2.62MN/A650
PRM
Proteome Sciences
N/AGBX 2
+5.3%		N/A-37.5%£7.01M£3.76MN/A240
GENI
GENinCode
N/AGBX 0.81
-2.4%		N/A-54.0%£6.06M£3.08MN/A2,300

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:IDHC) was last updated on 8/6/2026 by MarketBeat.com Staff.
From Our Partners
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
A Wall Street Veteran's Weekly Trade for Any Market Condition
Dave Aquino spent 25 years at Merrill Lynch and Vanguard studying one weekly options play that worked in bull,...
Base Camp Trading | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
This AI fund sends investors payouts every Thursday
CrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...
Investors Alley | Sponsoredtc pixel
This under $7 stock could be.
Just one mile from SpaceX's launchpad sits a small company doing something SpaceX can't - and it still trades ...
Freedom Financial | Sponsoredtc pixel
The dollar reset no one told you about
Porter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...
Porter & Company | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel